Journal Article
. 2014 May;19(7).
doi: 10.1634/theoncologist.2013-0471.

Current status of gene expression profiling to assist decision making in stage II colon cancer

Cheng E Chee 1 Neal J Meropol 2 
  • PMID: 24869929
  •     50 References
  •     7 citations


The decision regarding adjuvant therapy for patients with stage II colon cancer remains a challenge. In contrast to stage III colon cancer, for which compelling clinical data support the use of adjuvant chemotherapy, the clinical benefit of systemic therapy in unselected patients with stage II disease is modest at best. Risk stratification based on clinicopathologic features and DNA mismatch repair status is commonly used in adjuvant therapy decisions, but these factors do not have a desired level of precision in identifying patients at high risk. Recently, gene expression platforms have been developed to further define risk and to assist in therapeutic decision making for patients with stage II disease. This review describes those platforms that are furthest along in clinical development, in an effort to place their potential clinical application in context.

Keywords: Adjuvant therapy; Colon cancer; Genomic profiling; Stage II.

Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334519
Highly Cited.
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Greg Yothers, Michael J O'Connell, +7 authors, Norman Wolmark.
J Clin Oncol, 2013 Nov 14; 31(36). PMID: 24220557    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Capecitabine as adjuvant treatment for stage III colon cancer.
Chris Twelves, Alfred Wong, +23 authors, Werner Scheithauer.
N Engl J Med, 2005 Jul 01; 352(26). PMID: 15987918
Highly Cited.
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.
Wade S Samowitz, Carol Sweeney, +5 authors, Martha L Slattery.
Cancer Res, 2005 Jul 19; 65(14). PMID: 16024606
Highly Cited.
Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.
K Völp, M-L Brezniceanu, +5 authors, M Zörnig.
Gut, 2005 Aug 25; 55(2). PMID: 16118352    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
Stephanie Schulz, Terry Hyslop, +7 authors, Scott A Waldman.
Clin Cancer Res, 2006 Aug 11; 12(15). PMID: 16899600
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas, Arno Floore, +9 authors, Laura J Van't Veer.
BMC Genomics, 2006 Nov 01; 7. PMID: 17074082    Free PMC article.
Highly Cited.
The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis.
Douglas Iddings, Aziz Ahmad, David Elashoff, Anton Bilchik.
Ann Surg Oncol, 2006 Sep 30; 13(11). PMID: 17009147
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Leonard B Saltz, Donna Niedzwiecki, +5 authors, Robert J Mayer.
J Clin Oncol, 2007 Aug 10; 25(23). PMID: 17687149
Highly Cited.
Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature.
Daniel G Nicastri, John T Doucette, Tony E Godfrey, Steven J Hughes.
J Mol Diagn, 2007 Oct 06; 9(5). PMID: 17916603    Free PMC article.
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Quasar Collaborative Group, Richard Gray, +4 authors, David J Kerr.
Lancet, 2007 Dec 18; 370(9604). PMID: 18083404
Highly Cited.
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Scott A Waldman, Terry Hyslop, +6 authors, David S Weinberg.
JAMA, 2009 Feb 20; 301(7). PMID: 19224751    Free PMC article.
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Thierry André, Corrado Boni, +8 authors, Aimery de Gramont.
J Clin Oncol, 2009 May 20; 27(19). PMID: 19451431
Highly Cited.
GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
Alex Mejia, Stephanie Schulz, +2 authors, Scott A Waldman.
Expert Rev Mol Diagn, 2009 Nov 10; 9(8). PMID: 19895223    Free PMC article.
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Brody Winn, Rosemarie Tavares, +4 authors, Murray B Resnick.
Hum Pathol, 2009 Oct 06; 41(1). PMID: 19800103    Free PMC article.
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Arnaud D Roth, Sabine Tejpar, +14 authors, Fred Bosman.
J Clin Oncol, 2009 Dec 17; 28(3). PMID: 20008640
Highly Cited.
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Anna M Dahlin, Richard Palmqvist, +5 authors, Bethany R Van Guelpen.
Clin Cancer Res, 2010 Mar 04; 16(6). PMID: 20197478
Highly Cited.
Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes.
Jean-François Haince, Michel Houde, +10 authors, Yves Fradet.
J Clin Pathol, 2010 May 26; 63(6). PMID: 20498026
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.
C C Compton, L P Fielding, +12 authors, C Willett.
Arch Pathol Lab Med, 2000 Jul 11; 124(7). PMID: 10888773
Highly Cited. Review.
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
D J Sargent, R M Goldberg, +6 authors, G Francini.
N Engl J Med, 2001 Oct 13; 345(15). PMID: 11596588
Highly Cited.
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.
Deborah Schrag, Sheryl Rifas-Shiman, +2 authors, Colin B Begg.
J Clin Oncol, 2002 Sep 28; 20(19). PMID: 12351597
A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients.
Frederick L Greene, Andrew K Stewart, H James Norton.
Ann Surg, 2002 Oct 09; 236(4). PMID: 12368669    Free PMC article.
The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined.
Richard S Swanson, Carolyn C Compton, Andrew K Stewart, Kirby I Bland.
Ann Surg Oncol, 2003 Jan 07; 10(1). PMID: 12513963
Highly Cited.
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Christine M Ribic, Daniel J Sargent, +10 authors, Steven Gallinger.
N Engl J Med, 2003 Jul 18; 349(3). PMID: 12867608    Free PMC article.
Highly Cited.
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Sharlene Gill, Charles L Loprinzi, +12 authors, Richard M Goldberg.
J Clin Oncol, 2004 Apr 07; 22(10). PMID: 15067028
Highly Cited.
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
Al B Benson, Deborah Schrag, +10 authors, Daniel G Haller.
J Clin Oncol, 2004 Jun 17; 22(16). PMID: 15199089
Highly Cited. Review.
Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.
Jessica B O'Connell, Melinda A Maggard, Clifford Y Ko.
J Natl Cancer Inst, 2004 Oct 07; 96(19). PMID: 15467030
Highly Cited.
High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression.
H Tsushima, S Kawata, +8 authors, Y Matsuzawa.
Gastroenterology, 1996 Feb 01; 110(2). PMID: 8566583
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.
S A Waldman, B Cagir, +9 authors, D Weinberg.
Dis Colon Rectum, 1998 Mar 26; 41(3). PMID: 9514425
Micrometastases and survival in stage II colorectal cancer.
G J Liefers, A M Cleton-Jansen, +4 authors, R A Tollenaar.
N Engl J Med, 1998 Jul 23; 339(4). PMID: 9673300
Highly Cited.
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
Daniel J Sargent, Silvia Marsoni, +14 authors, Steven Gallinger.
J Clin Oncol, 2010 May 26; 28(20). PMID: 20498393    Free PMC article.
Highly Cited.
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
Michael J O'Connell, Ian Lavery, +9 authors, Norman Wolmark.
J Clin Oncol, 2010 Aug 04; 28(25). PMID: 20679606    Free PMC article.
Highly Cited.
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer.
Ramon Salazar, Paul Roepman, +16 authors, Rob Tollenaar.
J Clin Oncol, 2010 Nov 26; 29(1). PMID: 21098318
Highly Cited.
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
Gordon Hutchins, Katie Southward, +9 authors, Philip Quirke.
J Clin Oncol, 2011 Mar 09; 29(10). PMID: 21383284
Highly Cited.
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Frank A Sinicrope, Nathan R Foster, +9 authors, Daniel J Sargent.
J Natl Cancer Inst, 2011 May 21; 103(11). PMID: 21597022    Free PMC article.
Highly Cited.
Ongoing challenge of stage II colon cancer.
Neal J Meropol.
J Clin Oncol, 2011 Jul 27; 29(25). PMID: 21788557
Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.
Erin S O'Connor, David Yu Greenblatt, +4 authors, Maureen A Smith.
J Clin Oncol, 2011 Jul 27; 29(25). PMID: 21788561    Free PMC article.
Highly Cited.
Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
Daniel J Sargent, Murray B Resnick, +10 authors, Yves Fradet.
Ann Surg Oncol, 2011 May 03; 18(12). PMID: 21533822
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Richard G Gray, Philip Quirke, +10 authors, David J Kerr.
J Clin Oncol, 2011 Nov 10; 29(35). PMID: 22067390
Highly Cited.
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.
Richard D Kennedy, Max Bylesjo, +39 authors, D Paul Harkin.
J Clin Oncol, 2011 Nov 10; 29(35). PMID: 22067406
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Shuji Ogino, Kaori Shima, +13 authors, Charles S Fuchs.
Clin Cancer Res, 2011 Dec 08; 18(3). PMID: 22147942    Free PMC article.
Highly Cited.
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Christophe Tournigand, Thierry André, +8 authors, Aimery de Gramont.
J Clin Oncol, 2012 Aug 24; 30(27). PMID: 22915656
Highly Cited.
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Arnaud D Roth, Mauro Delorenzi, +10 authors, Eric Van Cutsem.
J Natl Cancer Inst, 2012 Oct 30; 104(21). PMID: 23104212
Highly Cited.
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
Patrick G Gavin, Linda H Colangelo, +14 authors, Kay L Pogue-Geile.
Clin Cancer Res, 2012 Oct 10; 18(23). PMID: 23045248    Free PMC article.
Highly Cited.
A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
John Hornberger, Gary H Lyman, Rebecca Chien, Neal J Meropol.
Value Health, 2012 Dec 19; 15(8). PMID: 23244802
Cancer statistics, 2013.
Rebecca Siegel, Deepa Naishadham, Ahmedin Jemal.
CA Cancer J Clin, 2013 Jan 22; 63(1). PMID: 23335087
Highly Cited.
Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.
Matthias Maak, Iris Simon, +10 authors, Robert Rosenberg.
Ann Surg, 2013 Jan 09; 257(6). PMID: 23295318
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
Katsuhiko Nosho, Hiroyuki Yamamoto, +6 authors, Kohzoh Imai.
Clin Cancer Res, 2004 Dec 09; 10(23). PMID: 15585629
Human CST abundance determines recovery from diverse forms of DNA damage and replication stress.
Feng Wang, Jason Stewart, Carolyn M Price.
Cell Cycle, 2014 Dec 09; 13(22). PMID: 25483097    Free PMC article.
Insight to drug delivery aspects for colorectal cancer.
Arvind Gulbake, Aviral Jain, +2 authors, Sanjay K Jain.
World J Gastroenterol, 2016 Jan 27; 22(2). PMID: 26811609    Free PMC article.
Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy.
Xiaogai Li, Shihai Wang, +7 authors, Liang Ming.
Cancer Biol Ther, 2016 May 26; 17(6). PMID: 27224726    Free PMC article.
Building personalized treatment plans for early-stage colorectal cancer patients.
Hung-Hsin Lin, Nien-Chih Wei, +9 authors, Jeng-Kai Jiang.
Oncotarget, 2017 Jan 19; 8(8). PMID: 28099153    Free PMC article.
MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma.
Melanie Rammer, Gerald Webersinke, +7 authors, Holger Rumpold.
Clin Exp Metastasis, 2017 Nov 15; 34(6-7). PMID: 29134398
Making sense of adjuvant chemotherapy in colorectal cancer.
Gloria H J Chan, Cheng E Chee.
J Gastrointest Oncol, 2020 Jan 18; 10(6). PMID: 31949938    Free PMC article.
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.
Eric Koncina, Serge Haan, Stefan Rauh, Elisabeth Letellier.
Cancers (Basel), 2020 Feb 06; 12(2). PMID: 32019056    Free PMC article.